Cue Biopharma
Evelyn Needham has five years of professional experience. Evelyn began their career as a Barista at The Skinny Pancake in 2014. In 2016, they became a Neuroscience Research Assistant at St. Lawrence University, where they studied the endocytosis mechanisms utilized by HT22 cells in the uptake of indium phosphide quantum dots (InPQDs) and the effect of cerium oxide nanoparticles on Multiple Sclerosis (PLP-EAE/MOG-EAE models) in murine models. Evelyn also served as a Chemistry Peer Workshop Leader, tutoring students in General Chemistry. In 2018, they interned at Harvard Medical School in the Sinclair Lab in the Department of Genetics, where they gained proficiency in confocal and phase-contrast microscopy, immunohistochemistry techniques, behavioral studies, and cell culture preparation. In 2019, they began working at McLean Hospital as a Technical Research Assistant I and II. In 2021, they joined Cue Biopharma as an Associate Scientist and Research Associate.
Evelyn Needham completed their Bachelor of Science in Neuroscience from St. Lawrence University in 2019. During their time there, they also attended the University of Otago in 2017 to study Chemistry.
This person is not in the org chart
Cue Biopharma
1 followers
Cue Biopharma is an innovative immunotherapy company dedicated to developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma’s Immuno-STAT Biologics are designed to engage directly with and modulate the activity of disease-associated T cells in the patient’s body, potentially offering significant therapeutic advantages while minimizing or eliminating unwanted side effects.